Myositis Clinical Trials
A listing of Myositis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 47 clinical trials
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (Progress)
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
- 0 views
- 09 Apr, 2023
- 17 locations
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM
- 0 views
- 04 Apr, 2023
Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (FALKON)
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to abnormal stiffening and immobility …
- 0 views
- 08 Apr, 2023
- 18 locations
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (Progress)
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
- 5 views
- 09 Apr, 2023
- 21 locations
The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)
The study population consists of patients with Fibrodysplasia ossificans progressiva (FOP). Key primary objectives are: To assess the effect of high dose garetosmab versus placebo on the formation of new heterotopic ossification (HO) lesions from baseline to week 56, as determined by low-dose computed tomography (CT) To assess the safety …
- 0 views
- 04 Apr, 2023
- 2 locations
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM (MYOJAK)
This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24
- 0 views
- 03 Jun, 2022
- 1 location
Adult Autoimmune Myopathies (MAIA) (MAIA)
This study corresponds to a monocentric prospective cohort of adult patients presenting a suspicion of idiopathic inflammatory myopathy. It will allows the constitution of an organized
- 0 views
- 04 Jun, 2022
- 1 location
Saracatinib Trial TO Prevent FOP (STOPFOP)
This is a phase 2 study, designed as a European multicentre 6-month double blind random-ized controlled trial (RCT) of AZD0530 versus matched placebo, followed by a 12 month trial comparing open-label extended AZD0530 treatment with historical control data. Study population: Male and female adult patients aged 18 years and older …
- 0 views
- 04 Oct, 2022
- 2 locations
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. (PIVOINE)
The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study …
- 0 views
- 09 Apr, 2023
- 2 locations
Multi-Center Study of ManNAc for GNE Myopathy (MAGiNE)
GNE myopathy is a rare genetic muscle disease characterized by progressive muscle atrophy and weakness. The disease is caused by mutations in the gene that encodes the enzyme that initiates and regulates N-acetylneuraminic acid (Neu5Ac) biosynthesis and glycan sialylation. Currently, there is no therapy available for this disease. N-Acetylmannosamine (ManNAc), …
- 0 views
- 09 Apr, 2023
- 10 locations